Illumina

Youtube Subscribe

Open: 129.65 Close: 129.11 Change: -0.54

You're losing the opportunity of using an AI to get informed about Illumina.

This document will help you to evaluate Illumina without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, Grail, EU, order, company, deal, biotech, and the …

Concept Map

Semantic Network

Stock Summary

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The company offers sequencing and array-based instruments and consumables, which include reagents, flow.

Today's Summary

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer screening company Grail. EU antitrust regulators on Thursday ordered Illumina. Shares of Illumina were down 2% at $135.06 in Thursday morning trading.

Today's News

Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Illumina technology had purportedly reduced the cost of sequencing a human genome to US$1,000. Illumina spun off the company Grail in late 2015, focused on blood testing for cancer tumors in the bloodstream. Francis deSouza took on the role of president and CEO. Illumina sued Oxford Nanopore Technologies for infringing its patents on the use of a biological nanopore. Illumina, Inc. (ILMN) stock price, quote & news - stock analysis. Analyst Consensus: Hold Stock Forecasts. Analyst consensus: Hold stock Forecasts News All Videos Press Press Press Releases Conversation Illumina. Illumina to announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023. The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims against Illumina. EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail. EU is ordering U.S. biotech giant to undo its $7 billion purchase. of cancer screening company Grail because it closed the deal without approval. Illumina shares slide after it slashes FY sales and profit forecast. Dr. Steven Barnard Appointed Chief Technology Officer. Illumina is improving human health by unlocking the power of the genome. The company operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields. Illumina is a major supplier of next-generation sequencing systems for genetic and genomic sequencing systems. The Federal Trade Commission ordered Illumina to sell Grail earlier this year after finding the merger would “stifle competition and innovation in the U.S. market. EU already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent. Illumina announced the acquisition of Grail in 2020, but the commission said the company broke EU merger rules by completing the deal without consent. EU orders biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc. The EU already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition. Shares of Illumina were down 2% at $135.06 in Thursday morning trading on the Nasdaq. EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail. Illumina ordered by EU antitrust regulators to sell cancer test maker Grail. U.S. genetic testing company Illumina (ILMNO) ordered by European Commission to sell Grail. Illumina estimated fair value is US$232 based on 2 Stage Free Cash Flow to Equity. Illumina posted a stewardship-focused presentation for investors on the Events & Presentations section of its investor relations website, investor.illumina.com. Members of Illuminas Board of Directors and senior management may use this presentation during meetings with investors. Illumina has yet to respond to the most recent order, but in general, we suspect the firms new management team will be more open to divesting Grail than the previous team. Morningstars top underpriced analyst picks for Q4 2023. EU antitrust regulators on Thursday ordered Illumina to divest Grail, after it completed the deal before securing their approval. The $7.1 billion deal was opposed on concerns that Illumina would have an incentive to stop Grails rivals from accessing its technology.

Stock Profile

"Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California."

Keywords

Are looking for the most relevant information about Illumina? Investor spend a lot of time searching for information to make investment decisions in Illumina. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, Grail, EU, order, company, deal, biotech, and the most common words in the summary are: illumina, grail, order, job, news, inc, company, . One of the sentences in the summary was: EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer screening company Grail. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #illumina #grail #order #job #news #inc #company.

Read more →

Youtube Subscribe

---